Long-Term Neuropsychological Outcomes from an Open-Label Phase I/IIa Trial of 2-Hydroxypropyl-β-Cyclodextrins (VTS-270) in Niemann-Pick Disease, Type C1
- 16 Downloads
Niemann-Pick disease, type C1 (NPC1) is a neurodegenerative condition that arises from mutations of NPC1 and is often diagnosed in children. Recently, several drug trials have been implemented to minimize neurodegeneration, including a trial of 2-hydroxypropyl-β-cyclodextrins (VTS-270).
The current study extends findings from a previous report of 18 months of disease severity data by describing neuropsychological outcomes over the course of 36 months post-baseline.
An open-label, dose-escalation phase I/IIa study of VTS-270 was performed in participants with NPC1 aged 4–23 years.
Fourteen participants were sequentially assigned to receive monthly initial intrathecal VTS-270 at doses of 50, 200, 300, or 400 mg per month. After initial dosing, participants were dose-escalated (to 600 or 1200 mg) as tolerated. Participants were evaluated at 6-month intervals using a standardized neuropsychological battery, including tests of cognition and adaptive behavior. A random effects model with restricted maximum likelihood estimation was constructed for each outcome, and the slope was the parameter of interest.
Findings based on IQ scores and both standard scores and age equivalents of adaptive functioning indicate that there were not meaningful declines in these areas during the study period. The average annualized change in Full Scale IQ was negative: B = − 1.28, standard error (SE) = 0.70, t(34.2) = − 1.83, p = 0.076. The Vineland-II Adaptive Behavior Composite standard score decreased by 1.76 points per year [SE = 0.67, t(59.1) = − 2.62, p = 0.011], but annualized slopes for each of the domain age equivalents were positive: Communication [B = 0.71, SE = 3.12, t(60.7) = 0.23, p = 0.82], Socialization [B = 2.99, SE = 2.92, t(60.4) = 1.03, p = 0.30], Daily Living Skills [B = 2.76, SE = 2.76, t(60.3) = 1.18, p = 0.24], and Motor Skills [B = 1.42, SE = 0.94, t(50.5) = 1.51, p = 0.14], indicating not worsening but slower-than-average acquisition of skills.
In conjunction with previous findings, these results provide support for the slowing of disease progress up to 36 months post-initiation of intrathecal VTS-270.
ClinicalTrials.gov identifier NCT01747135: Hydroxypropyl Beta Cyclodextrin for Niemann-Pick type C1 Disease.
We thank the study participants and their families.
Compliance with Ethical Standards
Conflict of interest
VTS-270 was provided by Janssen Pharmaceuticals, a Johnson & Johnson company. CAF, AT, NF, SB, LAK, and FDP have no other disclosures.
This research was supported by the Intramural Research Programs of the National Institute of Mental Health (1ZICMH002961) and the Division of Translational Research of the Eunice Kennedy Shriver National Institute of Child Health and Development (ZIA HD008824).
This study was approved by the Institutional Review Board of the Eunice Kennedy Shriver National Institute of Child Health and Human Development. All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.
Written informed guardian permission or participant consent was obtained. Assent was obtained when possible.
Data availability statement
The datasets analyzed during the current study are available from the corresponding author upon reasonable request.
- 9.Davidson CD, Ali NF, Micsenyi MC, Stephney G, Renault S, Dobrenis K, et al. Chronic cyclodextrin treatment of murine Niemann-Pick C disease ameliorates neuronal cholesterol and glycosphingolipid storage and disease progression. PLoS One. 2009;4(9):e6951. https://doi.org/10.1371/journal.pone.0006951.CrossRefGoogle Scholar
- 11.Ory DS, Ottinger EA, Farhat NY, King KA, Jiang X, Weissfeld L, et al. Intrathecal 2-hydroxypropyl-beta-cyclodextrin decreases neurological disease progression in Niemann-Pick disease, type C1: a non-randomised, open-label, phase 1–2 trial. Lancet. 2017;390(10104):1758–68. https://doi.org/10.1016/s0140-6736(17)31465-4.CrossRefGoogle Scholar
- 12.Wechsler D. Wechsler preschool and primary scale of intelligence. 3rd ed. San Antonio: Pearson; 2002.Google Scholar
- 13.Wechsler D. Wechsler intelligence scale for children. 4th ed. San Antonio: Psychological Corporation; 2003.Google Scholar
- 14.Wechsler D. Wechsler abbreviated scale of intelligence. San Antonio: Psychological Corporation; 1999.Google Scholar
- 15.Mullen EM, editor. Mullen scales of early learning. Circle Pines: American Guidance Service; 1995.Google Scholar
- 16.Sparrow SS, Cicchetti DV, Balla DA. Vineland adaptive behavior scales. 2nd ed. Circle Pines: AGS Publishing; 2005.Google Scholar
- 17.Sheslow D, Adams W. Wide range assessment of memory and learning second edition administration and technical manual. Lutz: Psychological Assessment Resources; 2003.Google Scholar
- 18.Hooper EH. Hooper visual organization test (VOT). Los Angeles: Western Psychological Services; 1983.Google Scholar
- 19.Beery KE, Beery NA. Beery VMI: the Beery-Buktenica developmental test of visual-motor integration with supplemental developmental tests of visual perception and motor coordination: and, stepping stones age norms from birth to age six. Administration, scoring, and teaching manual. San Antonio: PsychCorp; 2010.Google Scholar
- 20.Instrument L. Purdue pegboard test: user instructions. Lafayette: Lafayette Instrument; 2002.Google Scholar